Has David Scheck, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,573 in general payments to David Scheck, MD across 91 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Scheck, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Scheck, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Scheck, MD

Infectious Disease · Tulsa, OKNPI 1689642902

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Melinta Therapeutics, LLC at 47.5% of the total. Reporting peaked in 2019 at $3,164 and has fallen 98.2% since, to $56 in 2025.

$4,573in general payments, 2019–2025

Across 91 payments — averaging $50.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Melinta Therapeutics, LLC$2K
AbbVie$656
Viiv Healthcare Company$233
Merck$178
Novartis$137
Seagen Inc.$118
plus $1K from 25 others

What the payments were for

Speaking & faculty fees$2,10046%
Travel & lodging$80%
Food & beverage$2,43953%
Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Melinta Therapeutics, LLC	3	$2,171
AbbVie	7	$656
Viiv Healthcare Company	2	$233
Merck	4	$178
Novartis	8	$137
Seagen Inc.	8	$118
Bayer	6	$107
AstraZeneca	7	$100
Bristol Myers Squibb	6	$95
GSK	1	$80
Genentech USA, Inc.	4	$75
Takeda Pharmaceuticals U.S.A., Inc.	3	$61
Lilly USA, LLC	3	$58
Johnson & Johnson	3	$57
Blueprint Medicines Corporation	2	$42
Gilead	2	$41
Sanofi	2	$36
Array Biopharma Inc	2	$33
Astellas Pharma US Inc	2	$33
Eisai Inc.	2	$31
Paratek Pharmaceuticals, Inc.	2	$30
Pharmacyclics LLC, An Abbvie Company	2	$30
Kyowa Kirin, Inc.	2	$30
Ipsen Biopharmaceuticals, Inc	1	$27
Taiho Oncology, Inc.	1	$22
AMAG Pharmaceuticals, Inc.	1	$20
Amgen	1	$17
Clovis Oncology, Inc.	1	$16
Karyopharm Therapeutics Inc.	1	$15
Puma Biotechnology, Inc.	1	$12
Epizyme, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vabomere$2,100
DALVANCE$369
ZERBAXA$124
TEFLARO$121
TIVICAY$119
DOVATO$114
AVYCAZ$101

How this compares

$4,573 in reported general payments places this provider in the 85th percentile of 51 infectious disease providers in Oklahoma.

See all infectious disease providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$25,850

Medicare patients

Services billed

209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cefepime Hcl	31	$2,672
Fluconazole	24	$544
Azithromycin	38	$307
Cephalexin	17	$190
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	16	$35

Paid to pharmacies, not to this prescriber.

Other infectious disease in Tulsa

Peter OkwuasabaTulsa$15K
Heather BellTulsa$2K
Sristi BhattaraiTulsa$2K
Hosam MousselliTulsa$1K
Stephan HambazTulsa$729
Edemekong BasseyTulsa$688
Yasir AhmedTulsa$448
Anuj MalikTulsa$434
Ashley JenkinsTulsa$379
Janice TeTulsa$114

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →